Granite Bio
Basel, CH · 4 known investors
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
Founders & leadership
PL
Patrick LoustauPresident and Chief Executive Officer